Lifemd Inc SEC Filings

LifeMD, Inc. reported stronger Q3 2025 results, with total revenue rising to $60.2 million from $53.3 million a year earlier, driven by growth in telehealth and steady WorkSimpli software subscriptions. For the first nine months of 2025, revenue reached $187.0 million, up from $149.3 million in the prior-year period, while the operating loss narrowed sharply to $1.4 million from $14.4 million.

Net loss attributable to common stockholders improved to $4.6 million in the quarter and $7.9 million year-to-date, compared with $5.4 million and $18.8 million in the prior-year periods, despite ongoing preferred dividends of $2.3 million for the nine months. LifeMD generated $11.6 million of cash from operations year-to-date, repaid its remaining $14.0 million Avenue credit facility, and ended September 30, 2025 with $23.8 million in cash and positive stockholders’ equity of $3.4 million. Management states that existing cash should fund planned operations and capital needs for at least the next 12 months.

LifeMD, Inc. reported that it has released its financial results for the three and nine months ended September 30, 2025. The company disclosed in this report that a detailed press release with those results was issued on November 17, 2025 and is attached as Exhibit 99.1. The common stock trades on The Nasdaq Global Market under the symbol LFMD, and its 8.875% Series A Cumulative Perpetual Preferred Stock trades under the symbol LFMDP. This filing mainly serves to formally furnish the earnings press release under Item 2.02 of the Exchange Act.

LifeMD, Inc. (LFMD) filed a Form 12b-25 (NT 10-Q) to delay its Quarterly Report for the period ended September 30, 2025, stating it will file on or before the fifth calendar day following the due date. The company needs additional time to complete its financial statements and finalize adjustments to correct errors related to the over-recognition of revenue.

LifeMD identified approximately $4.6 million in cumulative over-recognized revenue across quarterly and annual periods between 2022 and June 30, 2025. The company states these adjustments will not affect its cash flow or cash position. It is also evaluating the potential impact on internal control over financial reporting. The company notes that its current and former independent registered public accounting firms have not audited, reviewed, or compiled the preliminary estimates.

LifeMD disclosed a scheduling change and accounting updates. The company rescheduled its third‑quarter 2025 earnings release and call to Monday, November 17, 2025, and expects to file a Form 12b‑25 for a late Form 10‑Q for the period ended September 30, 2025.

Management identified corrections after data system migrations affecting revenue recognition and related balance sheet accounts for the twelve months ended December 31, 2024 and the six months ended June 30, 2025. The cumulative impact is approximately $4.6 million, or about 1.4% of cumulative revenue for that period. The company states these adjustments will not materially change how reported revenue compared to guidance and will not affect cash flow or cash position.

LifeMD is evaluating potential implications for internal control over financial reporting. Preliminary determinations are subject to change as third‑quarter financials are prepared, and the company’s auditors have not performed procedures on these preliminary items.

LifeMD, Inc. completed the sale of 80% of WorkSimpli Software LLC to Lion Buyer, LLC, with signing and closing occurring simultaneously on November 4, 2025. The purchase price is based on an enterprise value of approximately $65.0 million, with $24.0 million paid at closing and up to an additional $28.0 million tied to future performance targets, for aggregate consideration of up to $52.0 million to the sellers.

At closing, the purchaser paid the estimated purchase price, with a portion held back as an adjustment holdback amount. The agreement includes customary representations, warranties, covenants, indemnification provisions, and closing deliverables. LifeMD also issued a press release announcing the transaction.

LifeMD (LFMD) director John R. Strawn Jr. reported an award of 22,365 restricted shares of common stock on October 6, 2025 at a price of $0. The filing states these restricted shares vest on June 1, 2026.

Following the grant, Strawn Jr. beneficially owned 413,001 shares directly and 60,000 shares indirectly through Strawn Pickens LLP.

LifeMD director Joan LaRovere reported a non‑derivative grant of 22,365 restricted shares of common stock acquired on 10/06/2025, increasing her beneficial holdings to 107,050 shares. The shares were granted at a price of $0, indicating they are restricted stock rather than a purchased award.

The grant carries a vesting condition: the restricted shares vest on June 1, 2026. This filing records a direct ownership change by a company insider; no options, conversions, or derivative instruments were reported.

LifeMD (LFMD) reported an insider equity award. A director acquired 22,365 shares of common stock on 10/02/2025 at a price of $0, as disclosed on Form 4. The filing notes this was a grant of restricted shares that vests on June 1, 2026. Following the award, the director beneficially owns 273,413 shares, held directly.

LifeMD, Inc. (LFMD) director Calum Archibald MacRae filed a Form 4 disclosing a non‑derivative grant of 22,365 restricted shares on 10/02/2025. The filing shows 38,865 total shares beneficially owned by the reporting person after the transaction. The restricted shares have a vesting condition: they vest on 06/01/2026. The transaction was reported on 10/06/2025 with a reported price of $0, consistent with a grant rather than an open‑market purchase.